Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Modular PMA Review Times Go Up; FDA Proposes Performance Goals

This article was originally published in The Gray Sheet

Executive Summary

FDA would like to incorporate Medical Device User Fee & Modernization Act performance goals into revised guidance for the modular PMA program

You may also be interested in...



More PMA Reviews Deferred As Device Center Meets MDUFMA Head-On

CDRH reviewers are placing more PMAs and 510(k) applications on hold in an effort to meet MDUFMA performance goals, according to the center's chief Donna-Bea Tillman

More PMA Reviews Deferred As Device Center Meets MDUFMA Head-On

CDRH reviewers are placing more PMAs and 510(k) applications on hold in an effort to meet MDUFMA performance goals, according to the center's chief Donna-Bea Tillman

Regulatory News In Brief

Modular PMA goals: FDA should complete review of 70% of PMA modules within 90 days, starting in fiscal 2006, AdvaMed proposes in Jan. 7 comments to FDA. Under the plan, 80% of modules would be completed in 90 days in 2007. AdvaMed's review performance targets differ from two proposals FDA offered at a November MDUFMA stakeholder meeting (1"The Gray Sheet" Nov. 29, 2004, p. 4). Under one agency option, 70% of modules would be completed within 120 days in 2006, rising to 80% in 2007. The alternative pledged 50% in 90 days in 2006, increasing to 60% in 2007. FDA's proposals "simply codify current performance levels, which have declined since the passage of MDUFMA," AdvaMed protests in its comments to FDA. Maintaining that user fees provide for additional review resources and that Congress has fully funded FDA for FY 2005 as required by MDUFMA, AdvaMed contends that its proposed targets for the agency are "reasonable and represent appropriate incremental improvement over current review performance"...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel